Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
AT ˙ WBAG ˙ US8816242098
€ 29,40 ↑1.40 (5.00%)
2026-06-04
PREÇO DA AÇÃO
SecurityAT:TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)
InstitutionBellevue Group AG
Latest Disclosed Ownership250,082 shares
Latest Disclosed Value $ 7,532,470
Bellevue Group AG reports 23.72% decrease in ownership of TEVA / Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock)

On May 14, 2026 - Bellevue Group AG filed a 13F-HR form disclosing ownership of 250,082 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock) (AT:TEVA) valued at $6,327,075 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 327,863 shares of Teva Pharmaceutical Industries Limited - Depositary Receipt (Common Stock). This represents a change in shares of -23.72% during the quarter. The current value of the position is $7,352,411 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 250,082 -77,781 -23.72 7,532 -26.39 0.1793
2026-02-17 2025-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 327,863 -96,193 -22.68 10,233 19.46 0.1939
2025-11-14 2025-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 424,056 2,555 0.61 8,566 21.25 0.1780
2025-08-14 2025-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 421,501 392,571 1,356.97 7,064 1,490.99 0.1557
2025-05-14 2025-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 28,930 -31,668 -52.26 445 -66.74 0.0100
2025-02-14 2024-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 60,598 -10,223 -14.43 1,336 4.62 0.0257
2024-11-14 2024-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 70,821 -83,949 -54.24 1,276 -49.26 0.0207
2024-08-14 2024-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 154,770 12,557 8.83 2,515 25.37 0.0409
2024-05-15 2024-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 142,213 142,213 2,007 0.0306
2020-08-13 2020-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 0 -303,000 -100.00 0 -100.00
2020-05-14 2020-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 303,000 37,000 13.91 2,721 4.37 0.0528
2020-02-14 2019-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 266,000 116,000 77.33 2,607 153.60 0.0413
2019-11-14 2019-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADS 881624209 150,000 150,000 1,028 0.0191
2019-05-15 2019-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 0 -60,000 -100.00 0 -100.00
2019-02-12 2018-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 60,000 0 0.00 925 -28.41 0.0608
2018-11-13 2018-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 60,000 -30,000 -33.33 1,292 -40.98 0.0820
2018-08-07 2018-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 90,000 0 0.00 2,189 42.33 0.1866
2018-05-09 2018-03-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 90,000 -581,940 -86.61 1,538 -87.92 0.1524
2018-02-14 2017-12-31 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 671,940 90,000 15.47 12,733 24.39 1.3302
2017-11-13 2017-09-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 581,940 296,611 103.95 10,236 7.99 1.0705
2017-08-14 2017-06-30 13F TEVA PHARMACEUTICAL INDS SPONSORED ADR 881624209 285,329 -80,843 -22.08 9,479 -19.33 1.1208
2017-05-11 2017-03-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 366,172 131,182 55.82 11,751 37.95 1.5659
2017-02-10 2016-12-31 13F TEVA PHARMACEUTICAL INDS ADR 881624209 234,990 47,800 25.54 8,518 -1.10 1.7444
2016-11-10 2016-09-30 13F Teva Pharmaceuticals Industries ADR 881624209 187,190 -42,000 -18.33 8,613 -25.18 1.5561
2016-08-12 2016-06-30 13F Teva Pharmaceuticals Industries ADR 881624209 229,190 33,900 17.36 11,512 10.16 2.1661
2016-05-16 2016-03-31 13F Teva Pharmaceuticals Industries ADR 881624209 195,290 195,290 10,450 1.8963
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.